Navigation Links
Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product
Date:2/28/2008

MORRISTOWN, N.J., Feb. 28 /PRNewswire/ -. Actavis Group, the international generic pharmaceuticals company, has received approval for Irinotecan Hydrochloride Injection from the U.S. Food & Drug Administration. Distribution of the product will begin immediately.

Irinotecan Hydrochloride Injection, the generic equivalent to Pfizer's Camptosar(R) will be available in 40 mg/2 mL and 100 mg/ 5 mL sizes and is used in the treatment of patients with metastatic carcinoma of the colon or rectum. Annual sales of Irinotecan Hydrochloride Injection in the United States were approximately US$556 million for the twelve months ending December 2007 according to IMS Health data.

Doug Boothe, Executive Vice President of US Commercial & Administration, said: "The launch of Irinotecan marks the expansion of Actavis' US portfolio into the injectable pharmaceuticals arena. Actavis has set its sights firmly on the hospital sector and currently has around 300 pending applications worldwide for injectable medicines. Furthermore, Actavis' ambitious pipeline comprises more than 60 new injectable projects, developed both internally and through established relationships with other developers."

Actavis currently markets over 50 hospital products worldwide, with a focus on oncology products and a growing range of anti-infectives, local anesthetics and analgesics.

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at http://www.actavis.us.

Information in this press release may c
'/>"/>

SOURCE Actavis Group
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
6. IsoTis Receives FDA Clearance for Accell Family of Products
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., , NOVATO, Calif., Nov. 30 /PRNewswire-Firs...MRN ) announced today that the Food and Drug Admin...n for 3,4-diaminopyridine (3,4-DAP), amifampridine...t Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has p...E.U. Also, in October 2009, the Committee for Med...
(Date:11/30/2009)..., , BOSTON and COPENHAGEN, Nov. 30 /PRNew...) announced today that the Harvard Medical School ... recognized as a MicroRNA Screening Center of Exce...Medical School, and associated hospitals and insti...lecule and RNAi libraries. ,, MicroRNAs are a n...
(Date:11/30/2009)..., , AMSTERDAM,...he world,s,leading publisher of scientific, medica...nced a major re-launch of Embase, its comprehensiv...indexed records from more than 7,000,active, peer ...ed a key role in the advancement of new biomedical...
(Date:11/27/2009)..., , DURHAM, N.C., Nov. 27 /PRNewswire...k, will initiate water-soluble carbon nanotube-bas.... The water-soluble carbon nanotubes, which have f...ugation with cancer drugs, was developed in partne...he conjugated carbon nanotubes serves as a drug de...
Breaking Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2
...assay for inhibition of poly(ADP-ribose) polymeras...es the inhibition of PARP-activated incorporation ...NAD). The incorporation is detected using Europium...way to screen test compounds for PARP activity in ...reening. , Poly(ADP-ribose) polymerase (PA...
...ts (QDs) have potential applications, ...emory devices, and sources of laser ..., herein to possess a nonlinear change ...correlated to size and composition, as monitored b...pectrofluorometer. The QDs, emission wavelength,...
... Many companies claim high sensitivity for their ...rument vendors often cite excitation of de-ionized...at 397 nm (an energy loss of 3380 cm 1 ). This Ram...nal is red-shifted and weak, thus mimicking weak f...making sample-to-sample reproducibility straightfo...
Other Biology Technology:A DELFIA Assay for Inhibition of PARP 2A DELFIA Assay for Inhibition of PARP 3Photoluminescence Spectroscopy of Quantum Dots, monitored by the Spex FluoroMax 2Photoluminescence Spectroscopy of Quantum Dots, monitored by the Spex FluoroMax 3Photoluminescence Spectroscopy of Quantum Dots, monitored by the Spex FluoroMax 4Wideband sensitivity of the FluoroLog-3 2
(Date:12/1/2009)...s an ,abominable mystery, and it is a question whi... when did flowering plants evolve and how did they...dy in Ecology Letters reveals the evolutionary t... a major competitive advantage over rival species,..., The study, by Dr Tim Brodribb and Dr Taylor Fi...
(Date:11/30/2009)... review of the state of Antarctica,s climate and i...blished this week (Tuesday 1 December) by the Scie...e review - Antarctic Climate Change and the Enviro...ontinent, identifies areas for future scientific r...olicy makers have about Antarctic melting, sea-lev...
(Date:11/30/2009)...of Pittsburgh team overcame a major hurdle plaguin...hat could lead to more efficient catalysts used to...c. The researchers reported Nov. 29 in Nature Mat...e stability in metallic nanoparticles, the vaunted...lity to extreme heat. , Gtz Veser, an associate ...
Breaking Biology News(10 mins):How did flowering plants evolve to dominate Earth? 2First comprehensive review of the state of Antarctica's climate 2First metallic nanoparticles resistant to extreme heat 2Sherman Oaks Hospital Opens New Cardiac Catheterization Laboratory and Reopens Behavioral Health Facility for Seniors 55349 1Sherman Oaks Hospital Opens New Cardiac Catheterization Laboratory and Reopens Behavioral Health Facility for Seniors 55349 2Sherman Oaks Hospital Opens New Cardiac Catheterization Laboratory and Reopens Behavioral Health Facility for Seniors 55349 3Iowa Drug Card a Huge Success With Iowans 55345 1Iowa Drug Card a Huge Success With Iowans 55345 2Burner Balm Responds to Barrage of UK Protests Over New Lip Balm 55340 1Burner Balm Responds to Barrage of UK Protests Over New Lip Balm 55340 2
... MADISON Pfizer Inc., a major biopharmaceutical ...ion (WARF), the private, nonprofit patenting and l...sin-Madison, announced May 5 that they have signed...ents for the development of new drug therapies. , ...rk with hES cells for drug research and discovery....
... , An effort is under way at the University of Hou...obile industry to develop new tools that will help...rapy for patients with head and neck cancer. , Dr... Free Form Fabrication Laboratory at UH and a form.... Lei Dong, associate professor and deputy researc...
... The National Center for Research Resources (NCRR...unced today it will provide up to an estimated $12...tional Development Award (IDeA) Networks of Biomed...gible states. By promoting the development, coordi...tise, these awards expand research opportunities a...
Other Biology News:WARF signs license agreement with Pfizer for human embryonic stem cells 2From cars to cancer: UH professor employs auto industry tools for tumor therapy 2From cars to cancer: UH professor employs auto industry tools for tumor therapy 3From cars to cancer: UH professor employs auto industry tools for tumor therapy 4NIH grants $122 million in Institutional Development Awards 2NIH grants $122 million in Institutional Development Awards 3
Anti-IRS 2, phospho (Ser731) Polyclonal Antibody, Unconjugated from BioSource International (Invitrogen)
... for non-denaturing polyacrylamide and agarose gel... solution contains a bromophenol blue tracking dye...loading. EDTA has been included to inhibit nucleas...added to help dissociate DNA-protein complexes whi...
Gel Loading Solution (Type I) from Sigma-Aldrich
Mouse Anti-Human QPRT Polyclonal Antibody, Unconjugated from Novus Biologicals
Biology Products: